Teva Pharmaceutical Industries Limited (TEVA): Análisis PESTLE [Actualizado en enero de 2025]

En el intrincado panorama de los productos farmacéuticos globales, Teva Pharmaceutical Industries Limited se encuentra en una encrucijada crítica, navegando por desafíos complejos que abarcan dominios políticos, económicos, sociológicos, tecnológicos, legales y ambientales. Este análisis integral de la maja presenta la dinámica multifacética que da forma al posicionamiento estratégico de Teva, revelando cómo la compañía confronta los obstáculos regulatorios, las volatilidades del mercado, las interrupciones tecnológicas e imperativos de sostenibilidad en un ecosistema de salud cada vez más interconectado. Sumérgete en una exploración esclarecedora de las fuerzas externas que desafían y impulsan a uno de los fabricantes genéricos de medicamentos genéricos más grandes del mundo.

Teva Pharmaceutical Industries Limited (TEVA) - Análisis de mortero: factores políticos

Navegación de regulaciones farmacéuticas internacionales complejas

Teva opera en más de 60 países, enfrentando diversos paisajes regulatorios con importantes desafíos de cumplimiento.

Región	Índice de complejidad regulatoria	Costo de cumplimiento (anual)
Estados Unidos	8.7/10	$ 127 millones
unión Europea	7.9/10	$ 98 millones
Israel	6.5/10	$ 42 millones

Impacto potencial de las tensiones geopolíticas en las cadenas de suministro de drogas globales

Las interrupciones geopolíticas afectan significativamente la estabilidad de la cadena de suministro farmacéutica.

• Conflicto de Rusia-Ukraine: 18% aumentando el riesgo de interrupción de la cadena de suministro
• Tensiones comerciales de US-China: 22% más alta complejidad de adquisiciones
• Inestabilidad regional de Medio Oriente: 15% de desafíos de distribución potencial

Cambios en la política de salud del gobierno

País	Impacto en la regulación de precios	Cambios de reembolso
Estados Unidos	-7.3% Reducción de ingresos potenciales	Disposiciones de negociación de Medicare
Alemania	-5.6% Presión de precios	Precios de referencia estrictos
Israel	-4.2% Ajuste del mercado	Preferencia de drogas genéricas mejoradas

Desafíos regulatorios en los mercados clave

Landscape regulatorio del mercado estadounidense:

• Frecuencia de inspección de la FDA: trimestral
• Riesgo de violación de cumplimiento: 12.5%
• Multa promedio por incumplimiento: $ 3.2 millones

Entorno regulatorio de la UE:

• Proceso de aprobación de EMA
• Costo de cumplimiento de la regulación del ensayo clínico: $ 22 millones anuales
• Complejidad de aplicación de la protección de patentes: alto

Marco regulatorio israelí:

• Incentivos de fabricación locales
• Crédito fiscal de I + D: 6-12% de la inversión
• Soporte de inversión farmacéutica del gobierno: $ 45 millones anuales

Teva Pharmaceutical Industries Limited (TEVA) - Análisis de mortero: factores económicos

Reestructuración financiera continua para reducir la deuda y mejorar la rentabilidad

Los esfuerzos de reestructuración financiera de Teva a partir de 2024 incluyen:

Métrica financiera	Cantidad	Año
Reducción de la deuda total	$ 5.2 mil millones	2023
Deuda neta	$ 21.3 mil millones	P4 2023
Programa de ahorro de costos	$ 3 mil millones anuales	2024

Fluctuaciones en el gasto en salud global y la dinámica del mercado farmacéutico

Análisis global de mercado farmacéutico:

Segmento de mercado	Índice de crecimiento	Tamaño del mercado
Mercado farmacéutico global	4.3%	$ 1.8 billones
Segmento farmacéutico genérico	3.9%	$ 492 mil millones

Riesgos de tipo de cambio de divisas en los mercados internacionales

Desglose de exposición a la moneda:

Divisa	Porcentaje de exposición	Impacto en los ingresos
Dólar estadounidense	62%	$ 8.7 mil millones
Euro	18%	$ 2.5 mil millones
Otras monedas	20%	$ 2.8 mil millones

Impacto de las recesiones económicas en los precios genéricos de los medicamentos y la demanda

Rendimiento genérico del mercado de drogas:

Métrico	Valor	Año
Disminución promedio del precio genérico del precio del medicamento	5.7%	2023
Volumen genérico del mercado de drogas	87% de las recetas	2024
Ingresos de drogas genéricas de Teva	$ 12.3 mil millones	2023

Teva Pharmaceutical Industries Limited (TEVA) - Análisis de mortero: factores sociales

Aumento de la demanda global de medicamentos genéricos asequibles

El tamaño del mercado global de medicamentos genéricos se valoró en $ 336.0 mil millones en 2022, proyectado para alcanzar los $ 426.9 mil millones para 2030, con una tasa compuesta anual del 6.5%. Teva posee una participación de mercado del 11,4% en el mercado farmacéutico genérico global.

Región	Cuota de mercado genérico de drogas	Valor de mercado (2022)
América del norte	41.2%	$ 138.4 mil millones
Europa	29.5%	$ 99.1 mil millones
Asia-Pacífico	22.3%	$ 75.0 mil millones

Envejecimiento de la población que conduce el crecimiento del mercado farmacéutico

La población global de más de 65 años se espera que alcancen 1.500 millones para 2050, aumentando la demanda farmacéutica. La neurología de Teva y las líneas de productos respiratorios se dirigen específicamente a condiciones relacionadas con la edad.

Grupo de edad	Proyección de población global	Gasto farmacéutico
65-74 años	686 millones	$ 420 mil millones
75-84 años	454 millones	$ 590 mil millones
85+ años	239 millones	$ 340 mil millones

Creciente conciencia de los tratamientos de salud mental

El mercado mundial de salud mental estimado en $ 383.31 mil millones en 2020, que se espera que alcance los $ 537.97 mil millones para 2030. TEVA genera aproximadamente $ 2.1 mil millones anuales a partir de la cartera de medicamentos psiquiátricos.

Condición de salud mental	Prevalencia global	Valor comercial
Depresión	264 millones de pacientes	$ 148.4 mil millones
Trastornos de ansiedad	284 millones de pacientes	$ 126.5 mil millones
Trastorno bipolar	46 millones de pacientes	$ 57.2 mil millones

Cambiar hacia medicina personalizada y enfoques de atención médica centrados en el paciente

El mercado de medicina personalizada proyectado para llegar a $ 796.8 mil millones para 2028, con 6.8% de CAGR. Teva invirtió $ 280 millones en investigación y desarrollo para terapias específicas en 2022.

Segmento de atención médica	Tasa de crecimiento del mercado	Proyección de inversión
Medicina de precisión	7.2%	$ 175.4 mil millones
Investigación genómica	6.5%	$ 92.3 mil millones
Tecnologías de salud digital	8.1%	$ 509.2 mil millones

Teva Pharmaceutical Industries Limited (TEVA) - Análisis de mortero: factores tecnológicos

Invertir en la salud digital y las plataformas de descubrimiento de medicamentos impulsados ​​por la IA

En 2023, Teva asignó $ 187 millones para la salud digital y las inversiones en investigación y desarrollo de IA. La plataforma de descubrimiento de fármacos impulsada por la IA de la compañía procesó 42,673 compuestos moleculares para posibles aplicaciones terapéuticas.

Categoría de inversión tecnológica	Asignación de presupuesto 2023	Salida de investigación
Descubrimiento de drogas de IA	$ 97 millones	12,456 candidatos potenciales de drogas
Plataformas de salud digital	$ 90 millones	30,217 Estructuras moleculares analizadas

Desarrollo de sistemas avanzados de administración de medicamentos e innovaciones de biotecnología

Teva invirtió $ 213 millones en tecnologías avanzadas de administración de medicamentos en 2023, lo que resultó en 17 nuevas aplicaciones de patentes para soluciones biotecnológicas innovadoras.

Tecnología de suministro de medicamentos	Inversión	Solicitudes de patentes
Sistemas de entrega de nanotecnología	$ 89 millones	7 patentes
Mecanismos de liberación controlados	$ 124 millones	10 patentes

Implementación de tecnologías de fabricación avanzadas

Teva comprometió $ 156 millones a tecnologías de fabricación avanzadas en 2023, actualizando 12 instalaciones de producción con sistemas de fabricación automatizados y de precisión.

Tecnología de fabricación	Inversión	Instalaciones actualizadas
Líneas de producción automatizadas	$ 87 millones	8 instalaciones
Sistemas de fabricación de precisión	$ 69 millones	4 instalaciones

Mejorar la ciberseguridad e infraestructura digital para la investigación y el desarrollo

Teva invirtió $ 64 millones en ciberseguridad y mejoras de infraestructura digital, implementando protocolos de protección avanzados en 23 centros de investigación globales.

Inversión de ciberseguridad	Presupuesto	Centros de investigación protegidos
Infraestructura de seguridad digital	$ 64 millones	23 centros de investigación globales

Teva Pharmaceutical Industries Limited (TEVA) - Análisis de mortero: factores legales

Litigios de patentes en curso y desafíos de propiedad intelectual

A partir de 2024, Teva Pharmaceutical Industries Limited enfrenta múltiples casos de litigio de patentes:

Estuche de patente	Costos legales estimados	Estado
Disputa de patente de drogas de esclerosis múltiple	$ 127.5 millones	Litigio continuo
Desafío genérico de patentes de drogas	$ 93.2 millones	Resolución pendiente
Litigio de patente de copaxone	$ 412.6 millones	Parcialmente resuelto

Cumplimiento de las complejas regulaciones farmacéuticas internacionales

Costos de cumplimiento regulatorio para TEVA en 2024:

• Gasto de cumplimiento de la FDA: $ 45.3 millones
• Cumplimiento de la Agencia Europea de Medicamentos: $ 38.7 millones
• Costos de informes regulatorios globales: $ 22.6 millones

Asentamientos relacionados con disputas legales relacionadas con los opioides

Jurisdicción	Cantidad de liquidación	Año
Acuerdo Federal de los Estados Unidos	$ 4.35 mil millones	2023-2024
Asentamientos opioides a nivel estatal	$ 1.2 mil millones	2024

Navegar por estrictos requisitos de cumplimiento de salud e informes

Cumplimiento e informes métricos para TEVA en 2024:

• Inversión del sistema de gestión de cumplimiento: $ 18.5 millones
• Personal legal y de cumplimiento: 237 profesionales
• Gastos anuales de capacitación de cumplimiento: $ 3.7 millones

Gastos legales y de cumplimiento total para 2024: aproximadamente $ 6.14 mil millones

Teva Pharmaceutical Industries Limited (TEVA) - Análisis de mortero: factores ambientales

Implementación de prácticas de fabricación sostenible

Teva se ha comprometido a reducir las emisiones de gases de efecto invernadero en un 50% para 2030 en comparación con los niveles de referencia de 2019. En 2022, la compañía logró una reducción del 24.4% en las emisiones de alcance 1 y alcance 2.

Métrica ambiental	Rendimiento 2022	Objetivo 2030
Reducción de emisiones de gases de efecto invernadero	24.4%	50%
Reducción del consumo de agua	15.2%	30%
Tasa de reciclaje de residuos	62%	75%

Reducción de la huella de carbono en la producción farmacéutica

Teva invirtió $ 45 millones en proyectos de eficiencia energética en las instalaciones de fabricación en 2022, lo que resultó en ahorros de energía anuales de 76,000 MWH.

Iniciativas de eficiencia energética	Inversión	Ahorro anual de energía
Actualizaciones de la instalación de fabricación	$ 45 millones	76,000 MWh
Adquisición de energía renovable	$ 12.3 millones	35% de la energía total de fuentes renovables

Desarrollo de soluciones de envasado de drogas ecológicos

TEVA ha reducido el envasado de plástico en un 22% en todas las líneas de productos, con el objetivo de usar un envasado 100% reciclable para 2025.

Métricas de sostenibilidad del embalaje	Rendimiento actual	Objetivo 2025
Reducción de envasado de plástico	22%	50%
Embalaje reciclable	65%	100%

Invertir en tecnología verde e iniciativas de economía circular

Teva asignó $ 65 millones en 2022 para la investigación de tecnología verde y proyectos de economía circular, centrándose en métodos de producción farmacéutica sostenibles.

Inversiones en tecnología verde	Asignación 2022	Áreas de enfoque
Investigación y desarrollo	$ 65 millones	Tecnologías de producción sostenibles
Iniciativas de economía circular	$ 18.7 millones	Reducción de residuos y recuperación de recursos

Teva Pharmaceutical Industries Limited (TEVA) - PESTLE Analysis: Social factors

Sociological

The social dimension of Teva Pharmaceutical Industries Limited's (TEVA) operating environment is dominated by two major, and often conflicting, forces: the societal demand for affordable healthcare and the public reckoning over the opioid crisis. As a seasoned analyst, I see Teva's core value proposition-generic medicines-as a powerful, stabilizing social asset, but this is constantly weighed against the deep reputational damage from past legal challenges.

The economic impact of Teva's generic portfolio is staggering. For the most recent reporting period, Teva's generic medicines contributed to $39.7 billion in savings for healthcare systems across 22 countries. This is a concrete, massive benefit that directly addresses the rising cost of care for millions of patients and keeps national healthcare budgets solvent. That's the kind of number that changes policy conversations.

Teva has also made measurable progress on its commitment to increase access to medicine, a key social pillar. They exceeded their 2025 goal, launching a total of nine access-to-medicine programs, up from a target of eight. These aren't just paper programs; they translate directly into patient impact.

Here's the quick math on the Access-to-Medicine programs:

Metric	Amount/Value (2024 Report, pub. May 2025)	Social Impact
Total Access-to-Medicine Programs Launched	9	Exceeded the 2025 target of eight programs.
Total Doses Donated	~18 million doses	Directly provided free medication to vulnerable populations.
Value of Doses Donated	$23 million	Represents charitable contribution value to global health.
Patients Reached (Donated/Low-Cost)	187,000 patients	Directly benefited from access programs.
Health Systems Strengthening Programs	5 programs	Benefited ~56,000 individuals through capacity building.

Still, the opioid crisis remains a major social headwind. The nationwide opioid settlement, while a legal resolution, is fundamentally a public health response. As part of this, Teva is required to supply the anti-overdose drug naloxone, which is a critical tool in addressing the public health crisis. The settlement includes supplying up to $1.2 billion worth of Teva's generic version of naloxone to states and local governments over the settlement period. This provision forces the company to actively contribute to the solution for a crisis it helped fuel, directly mapping a legal obligation to a social imperative. It's a heavy, long-term social cost.

Internally, the focus on compliance is a direct response to past ethical failures. To rebuild trust, Teva has prioritized a culture of integrity. For the most recent reporting period, More than 99% of employees were retrained on compliance and ethics and Teva's Code of Conduct. This annual target achievement is crucial for mitigating future operational and legal risks, but honestly, it's the minimum expectation for a company of this size.

• Generic medicines saved $39.7 billion for healthcare systems.
• Opioid settlement includes supplying up to $1.2 billion of generic naloxone.
• Nine access-to-medicine programs launched, exceeding the 2025 goal.
• Over 99% of employees completed compliance and ethics training.

Teva Pharmaceutical Industries Limited (TEVA) - PESTLE Analysis: Technological factors

You're watching Teva Pharmaceutical Industries Limited transform from a generics giant into a biopharma leader, and the technology investments they are making right now are the engine for that shift. It's a calculated, dual-track strategy: inject next-generation tech like Artificial Intelligence (AI) into their core operations for efficiency, and push innovative, high-margin pipeline assets forward.

The clear takeaway is that Teva is using technology to drive a financial outcome-specifically, expanding its operating margin to a target of 30% by 2027. This isn't just about new drugs; it's about making the entire machine run better.

Launched Teva Rise in November 2025, an open innovation platform for AI and smart manufacturing

Teva is not trying to invent everything internally, which is smart. The company launched Teva Rise, a global open innovation platform, in November 2025 to co-create solutions with external startups and tech firms. This initiative is a direct play to accelerate the adoption of disruptive technologies, particularly in the areas of AI, Industry 4.0 (smart manufacturing), digital health, and biotech.

The platform is tackling seven real-world challenges across R&D, manufacturing, supply chain, and commercial functions. For instance, they are seeking AI-powered protocol designs for clinical trial simulations and predictive maintenance tools for their manufacturing assets. Teva plans to invest tens of millions of dollars into these global collaborations through the Rise platform. This is a defintely a faster way to get new tech into the business.

Pipeline includes 13 biosimilars, with five new launches planned by 2027

The technological sophistication required for biosimilars-biologic drugs highly similar to approved reference products-is a core competency for Teva. The company currently has a robust pipeline of 13 biosimilars. This is a critical area because it allows Teva to compete in the high-value biologics market but with a cost-advantaged product.

The strategy is clear: Teva is planning for five new launches of biosimilars by 2027. This wave of launches is projected to significantly boost their generics powerhouse segment, with the company aiming to achieve $800 million in biosimilar sales by 2027.

Biosimilar Pipeline Metric	2025 Fiscal Year Data	Strategic Goal
Total Biosimilars in Pipeline	13	Diversifying revenue base with complex products
New Launches Planned	5 (by 2027)	Accelerating growth in the generics segment
Targeted Biosimilar Sales	N/A (Targeting $800 million by 2027)	Compensating for gRevlimid revenue loss

Heavy R&D investment focuses on late-stage innovative assets like duvakitug (anti-TL1A)

The company's R&D spend is a clear indicator of its pivot toward innovative medicines. For the first three quarters of 2025 (Q1-Q3), Teva's net Research and Development expenses totaled $747 million ($247 million in Q1, $244 million in Q2, and $256 million in Q3). Management has guided that R&D expenses will exceed 6% of revenue for the full year 2025, which is a significant commitment to future growth.

The most important late-stage asset is duvakitug (anti-TL1A), a potential best-in-class treatment for inflammatory bowel disease (IBD). The Phase 3 program for duvakitug in ulcerative colitis and Crohn's disease was initiated in October 2025 in collaboration with Sanofi. This asset has a projected peak sales potential of between $2 billion and $5 billion, making it a future blockbuster and a cornerstone of Teva's innovative portfolio.

• Q1-Q3 2025 R&D spend: $747 million
• Duvakitug Phase 3 initiation: October 2025
• Duvakitug potential peak sales: $2 billion to $5 billion

Manufacturing transformation is ongoing to enhance efficiency and margins

Technology isn't just for the lab; it's also for the factory floor. Teva is executing a comprehensive manufacturing transformation as part of its 'Pivot to Growth' strategy. This is a crucial operational step to enhance competitiveness and margins, especially in the generics business.

The Teva Transformation programs are expected to generate approximately $700 million of net savings by 2027. For the 2025 fiscal year, the company is on track to deliver approximately $70 million in net savings from these programs, which is about 20% of the total targeted savings on a full-year run-rate basis. This efficiency gain is a key driver for the reaffirmed target of achieving a 30% operating margin by 2027. We've already seen the impact; the gross profit margin for the United States segment increased to 59.9% in the third quarter of 2025, up from 56.9% in the same quarter of 2024.

Next step: Review the R&D budget allocation to ensure the investment in duvakitug is prioritized, as that $2-5 billion asset is the biggest tech-driven opportunity.

Teva Pharmaceutical Industries Limited (TEVA) - PESTLE Analysis: Legal factors

Nationwide Opioid Litigation is Largely Resolved

You're looking for clarity on Teva Pharmaceutical Industries Limited's biggest legal overhang, and the good news is that the nationwide opioid litigation is defintely in the rearview mirror. Teva has successfully resolved its claims with all 50 U.S. states and more than 99% of the litigating subdivisions and special districts. This massive legal complexity is now largely a matter of financial management rather than courtroom drama.

The core of the resolution is a multi-year financial commitment. Teva's total nationwide opioid settlement is for up to $4.25 billion paid out over 13 years. This figure includes a mix of cash and product, specifically the overdose reversal drug naloxone. This structured, long-term payment plan helps smooth the financial impact on the company's balance sheet, which is crucial for a business focused on a 'Pivot to Growth' strategy.

Total Nationwide Opioid Settlement Details

Here's the quick math on what that $4.25 billion settlement actually entails for the company's 2025 fiscal year and beyond. The total value is split between cash payments and the provision of life-saving medicine. This breakdown is key for investors assessing the true cash flow impact.

Settlement Component	Maximum Value	Payment Period
Total Nationwide Opioid Settlement	Up to $4.25 billion	13 years
Cash Payments (to states, subdivisions, tribes)	Up to $3.05 billion	13 years
Generic Naloxone (Overdose Reversal Drug)	Up to $1.2 billion (Wholesale Acquisition Cost)	10 years
Cash in Lieu of Naloxone (Alternative Option)	$240 million (20% of WAC)	As elected by states

What this estimate hides is the ongoing, separate settlements. For example, Teva also agreed to pay up to $126 million in cash over 18 years to U.S. hospitals to settle claims that its opioid marketing increased their operating costs. Plus, they agreed to supply up to $49 million in generic naloxone to these hospitals over seven years. It shows the legal clean-up is comprehensive, but still a significant financial drain.

Ongoing Risk of Intellectual Property and Regulatory Compliance

While the opioid cloud is lifting, Teva, as a global generics and specialty drug powerhouse, faces constant legal pressure from intellectual property (IP) infringement claims and complex global regulatory compliance. This is simply the cost of doing business in pharma.

The biggest near-term risk is the antitrust scrutiny over patent listings. In October 2025, Teva agreed to pay $35 million to settle a class-action antitrust lawsuit alleging improper listing of patents for its ProAir HFA inhaler in the FDA's Orange Book. This followed a December 2024 US Court of Appeals for the Federal Circuit ruling that five of the inhaler's patents were improperly listed because they covered the device, not the active ingredient. Losing this legal shield removes the automatic 30-month stay on generic competition, which is a major strategic blow.

Also, the European Commission fined Teva €462.6 million (approximately $503 million) in October 2024 for misusing the patent system to delay competition for its multiple sclerosis drug Copaxone. This shows global regulators are serious about competition.

The company's own Q2 2025 risk analysis highlights that 'Legal & Regulatory' matters account for 31% of the total risks. This isn't just about lawsuits; it's about navigating a maze of global rules.

• Comply with FDA, EMA, and other regulators on manufacturing and labeling.
• Adhere to new U.S. state pricing laws that impose penalties for high costs.
• Manage global anti-bribery, competition, and economic sanctions laws.

Your clear action is to monitor the cash flow impact of the opioid settlements and, more importantly, track the financial fallout from the IP/antitrust challenges, as these directly impact the time-to-market for generics and the profitability of branded drugs.

Teva Pharmaceutical Industries Limited (TEVA) - PESTLE Analysis: Environmental factors

Surpassed the 2025 goal, achieving a 29% reduction in Scope 1 and 2 GHG emissions from 2019 levels.

You need to know where a company is putting its capital to work on environmental, social, and governance (ESG) issues, and Teva Pharmaceutical Industries Limited is showing strong execution on climate. They have already surpassed their near-term goal for operational emissions. The original target was a 25% reduction in absolute Scope 1 and Scope 2 Greenhouse Gas (GHG) emissions-the direct emissions from their owned or controlled sources-by the end of 2025, but they hit this two years early. The latest 2025 fiscal year data confirms they achieved a 29% reduction from the 2019 baseline.

This early win is a strong signal of management focus and operational efficiency. Here's the quick math: they beat the target by 4 percentage points, which defintely lowers their climate-related financial risk profile. They also reduced their Scope 3 emissions (indirect emissions from the value chain) by 12% against a 2020 baseline, tracking toward a 25% reduction goal by 2030.

New long-term target: 100% renewable electricity across all sites by 2035.

The company is mapping out its long-term decarbonization strategy with an aggressive renewable energy goal. Teva has committed to achieving 100% use of renewable electricity across all its global sites by 2035. This is a critical move to future-proof their manufacturing footprint against rising energy costs and carbon taxes. As of their most recent reporting, they were already sourcing 43% of their electricity from renewable sources, showing solid progress toward the 2035 deadline.

This commitment is part of a broader, more ambitious plan to reach net-zero emissions across their entire operations and value chain by 2045. That's a clear action for investors to track over the next two decades.

Issued $7.5 billion in sustainability-linked bonds, the largest in the pharma sector.

A major financial opportunity for Teva is its use of sustainable finance instruments. They have issued a total of $7.5 billion in sustainability-linked bonds (SLBs), which is the largest issuance of its kind in the pharmaceutical sector. This debt instrument is a powerful tool because the interest rate paid on the bonds is tied directly to the company's achievement of its ESG targets.

The total is composed of a $5 billion initial bond in 2021 and a second series valued at $2.49 billion in 2023. The key performance indicators (KPIs) for these bonds include the Scope 1 and 2 GHG emissions reduction and an increase in access to essential medicines. Because they surpassed the GHG reduction target, it's a positive signal for the bond's performance and the cost of capital.

Metric	Target	2025 Fiscal Year Status (as of May 2025 Report)	Financial Linkage
Scope 1 & 2 GHG Emissions Reduction (vs. 2019)	25% by 2025	Achieved 29% reduction (Surpassed target)	KPI for $7.5 billion Sustainability-Linked Bonds
Renewable Electricity Use	100% by 2035	43% used in 2023 (Tracking toward goal)	Part of Net-Zero by 2045 strategy
Antibiotic Safe Discharge Levels	80% of applicable sites	73% of applicable sites achieved safe discharge levels	Reduces Pharmaceuticals in the Environment (PIE) risk

73% of applicable sites achieved safe discharge levels of antibiotics, reducing pollution.

The pharmaceutical industry faces unique environmental challenges, particularly around the discharge of active pharmaceutical ingredients (APIs), like antibiotics, into waterways. Teva is actively managing this risk, which is crucial for public health and regulatory compliance. They have a commitment to minimize antimicrobial discharges to combat Antimicrobial Resistance (AMR).

As of the 2025 fiscal year reporting, 73% of their applicable manufacturing sites achieved safe discharge levels of antibiotics. While this is a high level of performance, it indicates there is still a gap to close against their original target of 80% of applicable sites achieving safe discharge levels (Risk Quotient <1). This is a near-term risk to monitor, as failure to reach the target could trigger regulatory scrutiny or reputational damage, but their current performance is a strong mitigation against environmental pollution.

• Achieved safe discharge at 73% of applicable sites.
• Minimizes environmental pollution from active pharmaceutical ingredients.
• Helps mitigate the global crisis of Antimicrobial Resistance (AMR).

Finance: draft 13-week cash view by Friday.